Calcitonin (medullary thyroid carcinoma surveillance — MEN2 carriers)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CALCITONIN-MTC |
|---|---|
| Type | Biomarker |
| Aliases | CTNCalcitoninserum calcitoninКальцитонін (нагляд медулярного раку щитоподібної залози — носії MEN2) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-MTC |
| Sources | SRC-ENDOCRINE-SOCIETY-MEN-2023 SRC-NCCN-THYROID-2025 |
Biomarker Facts
| Biomarker type | serum_marker |
|---|---|
| Measurement | MethodSerum two-site immunometric assay (calibrated against IRP 89/620 or equivalent) Unitspg/mL Typical range
|
| Related biomarkers | None declared |
Notes
Parafollicular C-cell secretory product — highly specific biomarker for medullary thyroid carcinoma (MTC) and C-cell hyperplasia. ATA 2015 / NCCN 2025 surveillance for MEN2A/MEN2B carriers who DEFER prophylactic thyroidectomy (rare, high-risk-codon discussion only): annual basal calcitonin + neck US starting at age 3-5 (MEN2B) or 5 (MEN2A high-risk codon) or 5-10 (MEN2A intermediate/low). Pentagastrin/calcium-stimulated calcitonin historically used; pentagastrin no longer manufactured in many regions. Basal calcitonin >10 pg/mL in MEN2 carrier → strong indication for prophylactic thyroidectomy. After thyroidectomy (prophylactic or therapeutic): post-operative calcitonin used to assess cure (<2 pg/mL = biochemical cure) and detect recurrence (q6-12 month surveillance). Calcitonin doubling time <6 months = aggressive recurrence (worst prognosis). Procalcitonin can replace if assay available. Falsely elevated in renal failure, pregnancy, autoimmune thyroiditis. STUB pending two-Co-Lead signoff.
Used By
Actionability
BMA-CALCITONIN-MTC-MEN2-SURVEILLANCE- Serum calcitonin is a highly specific biomarker for medullary thyroid carcinoma (MTC) — p...